Overview
VIR market data
Price History
VIR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.16 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.61 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.16 – $11.66 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.5K · P/B 1.10 · P/S 21.30.
Company News
Vir Biotechnology Appoints Brent Sabatini To Interim Principle Financial Officer Effective July 23 As The Company Begins Search For CFOBenzinga · Jul 24, 2026, 12:32 PM
8-K filing — Vir Biotechnology, Inc. (VIR)SEC EDGAR · Jul 24, 2026, 12:31 PM
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27Benzinga · Jun 11, 2026, 12:30 PM
Vir Biotechnology To Present Data From Its Phase 2 SOLSTICE Study Of Obevibart And Elebsiran Combination To Treat Chronic Hepatitis DeltaBenzinga · May 18, 2026, 8:10 PM
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesGlobenewswire Inc · May 14, 2026, 3:15 PM